Ani Pharmaceuticals (ANIP) EV to FCF (2013 - 2026)

Ani Pharmaceuticals has disclosed EV to FCF across 14 years of filings, most recently posting 30.11 for Q2 2026.

• In Q2 2026, EV to FCF rose 74.52% year-over-year to 30.11; the TTM figure through Jun 2026 stood at 9.33 (down 5.5% YoY), while the FY2025 annual figure was 8.69, down 59.36% from the prior year.
• EV to FCF came in at 30.11 for Q2 2026 at Ani Pharmaceuticals, up from 28.98 in the prior quarter.
• In the past five years, EV to FCF ranged from a high of 433.91 in Q3 2022 to a low of 86.33 in Q4 2022.
• Average EV to FCF over 5 years is 58.52, with a median of 37.57 recorded in 2023.
• The largest YoY upside for EV to FCF was 743.27% in 2022 against a maximum downside of 188.77% in 2022.
• Over 5 years, EV to FCF stood at 86.33 in 2022, then surged by 125.15% to 21.71 in 2023, then soared by 249.51% to 75.89 in 2024, then tumbled by 32.59% to 51.16 in 2025, then tumbled by 41.14% to 30.11 in 2026.
• Per Business Quant data, the three most recent EV to FCF figures were 30.11 in Q2 2026, 28.98 in Q1 2026, and 51.16 in Q4 2025.